JPRN-jRCT2080223773已完成2 期
A phase IIb, clinical trial to study the safety and efficacy of Pembrolizumab (MK-3475) in combination with TS-1+Cisplatin or TS-1+Oxaliplatin as a First Line Chemotherapy in participants with Advanced or Recurrent Gastric Cancer (KEYNOTE-659)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale at the timing of enrollment.
- •- Have histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
- •- Have a PD-L1 positive tumor as determined by IHC at a central laboratory.
- •- Have measurable disease as defined by RECIST 1.1 as determined by investigator assessment.
- •Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- •- Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication.
- •- Male subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.
- •- Demonstrate adequate organ function.
排除标准
- •- Has squamous cell or undifferentiated gastric cancer.
- •- Participants with human epidermal growth factor receptor 2 (HER2)-positive status.
- •- Has had previous therapy for locally advanced, unresectable or metastatic gastric/GEJ cancer.
- •- A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •- Has received prior therapy with a platinum-based anti-cancer drug.
- •- Has had major surgery, open biopsy or significant traumatic injury within 28 days prior to enrollment, or anticipation of the need for major surgery during the course of study treatment.
- •- Has had radiotherapy within 14 days of enrollment.
- •- Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.
- •Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that have undergone potentially curative therapy are not excluded.
- •- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •- Has an active autoimmune disease that has required systemic treatment in past 2 years.
- •- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •- Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- •- Has an active infection requiring systemic therapy.
- •- Being on flucytosine at the time of enrollment.
- •- Has grade 2 or more peripheral sensory neuropathy.
- •- Has poorly controlled diarrhea (e.g., watery stool, uncontrollable bowel movement with drugs, grade 2 or more and number of defecations, 5 or more/day).
- •- Accumulation of pleural, ascitic, or pericardial fluid requiring drainage within 2 weeks prior to enrollment.
- •- Has a history or current evidence of any condition (e.g. known deficiency of the enzyme dihydropyrimidine dehydrogenase [DPD]), therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •- Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.
- •- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.
- •- Has a known history of Human Immunodeficiency Virus (HIV).
- •- Has a known history of Hepatitis B or known active Hepatitis C virus infection.
- •- Is currently participating in and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of trial treatment.
- •- Has received a live vaccine within 30 days of planned start of study therapy.
研究者
相似试验
已完成
不适用
A Phase 2 clinical trial to evaluate the safety and efficacy of cone beam CT guided video assisted thoracoscopic partial resection for impalpable small pulmonary nodulesmalignant pulmonary noduleJPRN-UMIN000030388General Thoracic Surgery, Chiba University Hospital20
进行中（未招募）
不适用
A phase II clinical trial to evaluate the safety and efficacy of interferon gamma in elevating frataxin levels in Friedreich ataxia patientsEUCTR2012-001881-14-ITAZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
招募中
不适用
Phase II clinical trial to evaluate the safety and efficacy of particle radiotherapy preceded atezolizumab plus bevacizumab treatment in patients with unresectable multiple hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000048296Kobe University43
进行中（未招募）
1 期
Trial to evaluate the safety and efficacy of a research drug in combination with antiretroviral treatment to cure people infected with HIV-1 without antiretroviral treatment.EUCTR2018-000497-30-ESFundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)12
进行中（未招募）
不适用
Clinical phase II trial to evaluate the safety and efficacy of clofarabine and treosulfan conditioning prior to peripheral blood stem cells transplantation in paediatric and adult patients with advanced haematological malignancies - NDpatients affected by advanced haematological malignanciesMedDRA version: 9.1Level: HLGTClassification code 10018865Term: Haematopoietic neoplasms (excl leukaemias and lymphomas)EUCTR2008-006972-31-ITOSPEDALE S. RAFFAELE